… minimally pretreated patient with non-small cell lung cancer (NSCLC). Stable disease for
4-7… and non-small cell lung cancers. Analysis of normal skin and tumor biopsies is under way …

… treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy
… non-small-cell lung cancer. Lung cancer has been estimated to be the leading cause of …

… were 105 deaths in erlotinib arm versus 70 in placebo. The majority of early deaths in
TRIBUTE were attributed to progression of underlying lung cancer (78% erlotinib, 87% placebo). …

… erlotinib … Lung Cancer Symptom Scale). Sample size of 1050 was based on 80% power to
detect a 25% benefit in OS, α=0.05. Results: 1059 pts were randomized / treated (526 erlotinib…

… been described for the synthesis of erlotinib hydrochloride, as a useful drug in treatment of
non-small-cell lung cancer. Method: Erlotinib hydrochloride was synthesized in seven steps …

… Erlotinib (Tarceva) is a reversible and highly specific inhibitor of epidermal growth factor …
with EGFR-positive non-small cell lung cancer after failure of platinum-containing chemotherapy …

… Cell Lung Cancer (NSCLC) and Pancreatic Cancer. A detailed description of different
mechanisms involved in erlotinib action … Erlotinib hydrochloride salt has an equilibrium solubility of …

… Erlotinib hydrochloride is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,…
erlotinib hydrochloride (27.3, 109.3, or 164 mg) equivalent to 25, 100, or 150 mg of erlotinib. …

… In phase II clinical studies, oral erlotinib monotherapy has shown antitumor activity in
patients with advanced non–small cell lung cancer, head and neck cancer, and ovarian cancer …

… Lung cancer is the leading cause of cancer death among men and women in North America.
In advanced non–small-cell lung cancer… TRIBUTE -- a phase III trial of erlotinib HCl (OSI-774…